Inhibition of Renal Sodium–Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Diabetes

• Publication date

  2017-06-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2337/db17-0055PMID 28611037PMCID PMC7301341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amendment history : Corrigendum ( May 2014 ) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

  2018influential reference
• Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients

  2017cited by this paper
• Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

  2015cited by this paper
• Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

  2014cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• Prevention of Diabetes With Pioglitazone in ACT NOW

  2013influential reference
• Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and its Association with Complications in Patients with type 2 Diabetes Mellitus

  2012cited by this paper
• Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance

  2012cited by this paper
• Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose

  2011cited by this paper
• Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

  2011cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance Results From the Veterans Administration Genetic Epidemiology Study

  2006cited by this paper
• Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes.

  2006cited by this paper
• Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance

  2006cited by this paper
• Different Mechanisms for Impaired Fasting Glucose and Impaired Postprandial Glucose Tolerance in Humans A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

  2006cited by this paper
• Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose.

  2006influential reference
• Contributions of β-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

  2006cited by this paper
• Loss of beta cell function as fasting glucose increases in the non-diabetic range

  2004cited by this paper
• Who are more insulin resistant, people with IFG or people with IGT?

  2004cited by this paper
• Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study

  2003cited by this paper
• Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

  2002influential reference
• The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

  2001influential reference
• Glucose toxicity.

  2001cited by this paper
• Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance

  1995cited by this paper
• Glucose Toxicity

  1990cited by this paper
• Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.

  1989cited by this paper
• Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

  1989cited by this paper
• Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man

  1983cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979influential reference

• Epiregulin ameliorates ovariectomy-induced bone loss through orchestrating the differentiation of osteoblasts and osteoclasts.

  2025cites this paper
• Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes

  2024cites this paper
• Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

  2024cites this paper
• Beta‐cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?

  2023cites this paper
• The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals

  2023cites this paper
• Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia

  2023cites this paper
• New-onset diabetes with sodium-glucose cotransporter-2 inhibitors in prediabetes: An updated meta-analysis and possible mechanisms.

  2023cites this paper
• Pharmacokinetics and Bioequivalence of Two Empagliflozin, with Evaluation in Healthy Jordanian Subjects under Fasting and Fed Conditions

  2022cites this paper
• Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review

  2022cites this paper
• GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis

  2022cites this paper
• Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function

  2022cites this paper
• SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease.

  2022cites this paper
• Persistent Inflammatory Lipotoxicity Impedes Pancreatic β-cell Function in Diet-Induced Obese Mice Despite Correction of Glucotoxicity

  2022influential citation
• Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.

  2021cites this paper
• Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome

  2021cites this paper
• Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class

  2021cites this paper
• Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state

  2021cites this paper
• Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update

  2020cites this paper
• No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE‐D trial

  2020cites this paper
• SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

  2020cites this paper
• BMP9 Reduces Bone Loss in Ovariectomized Mice by Dual Regulation of Bone Remodeling

  2020cites this paper
• Research Protocol “Effect of quadruple therapy on pancreatic islet function, insulin resistance and cardiovascular function in patients with mixed prediabetes and obesity: Randomized Clinical Trial”

  2019cites this paper
• Renal Specific RNAi Delivery by Fibrillar Nanoparticle Excipients

  2019cites this paper
• Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice

  2019cites this paper
• The Presence of Prediabetes in Patients With Heart Failure-A New Venue for the Sodium-Glucose Co-Transporter 2 Inhibition?

  2018cites this paper
• Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

  2017cites this paper
• Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions.

  2017cites this paper